Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
9.14
-0.28 (-2.97%)
At close: Jun 27, 2025, 4:00 PM
9.51
+0.37 (4.05%)
After-hours: Jun 27, 2025, 7:27 PM EDT
Alvotech Revenue
Alvotech had revenue of $132.81M in the quarter ending March 31, 2025, with 259.97% growth. This brings the company's revenue in the last twelve months to $587.89M, up 413.92% year-over-year. In the year 2024, Alvotech had annual revenue of $491.98M with 426.84% growth.
Revenue (ttm)
$587.89M
Revenue Growth
+413.92%
P/S Ratio
4.30
Revenue / Employee
$580,919
Employees
1,012
Market Cap
2.77B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ALVO News
- 1 day ago - Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility - GlobeNewsWire
- 2 days ago - Main Results of 2025 Annual and Extraordinary General Meeting - GlobeNewsWire
- 2 days ago - Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewsWire
- 2 days ago - Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewsWire
- 4 days ago - European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept) - GlobeNewsWire
- 4 days ago - European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept) - GlobeNewsWire
- 16 days ago - Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors - GlobeNewsWire
- 16 days ago - Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors - GlobeNewsWire